GO
Loading...

Novartis AG

More

  • Novartis' blood cancer drug wins U.S. approval Monday, 23 Feb 2015 | 3:18 PM ET

    Feb 23- The U.S. Food and Drug Administration approved Novartis AG's drug for treating a form of cancer that affects white blood cells. Multiple myeloma causes these cells to rapidly multiply and crowd out healthy blood cells from the bone marrow. The drug, Farydak, slows the multiplication of cells or causes them to die by blocking the activity of certain enzymes...

  • WASHINGTON, Feb 23- Novartis AG has won U.S. antitrust approval to buy GlaxoSmithKline's oncology drugs, with conditions, the U.S. Federal Trade Commission said on Monday. The deal is one of three related transactions announced in April 2014 in which GlaxoSmithKline would buy Novartis' global vaccine business, except for flu vaccines, Novartis would buy Glaxo's...

  • LONDON, Feb 17- Bonds issued by European blue chips such as EDF, Nestle and Royal Dutch Shell have slipped into negative-yield territory as investors seek refuge from sub-zero central bank rates. The European Central Bank's monetary easing measures- including a deposit rate at -0.2 percent and a pledge to buy 1 trillion euros of bonds- have turned bond markets on...

  • WASHINGTON, Feb 10- For the first time in 20 years, patients suffering from the eye disease glaucoma may soon have new treatments as several young companies look to shake up the $5.6 billion global market. No new class of medicine has been introduced since Pfizer Inc's N> Xalatan, known generically as latanoprost, in 1996.. The newcomers aim to disrupt...

  • *Q4 adjusted EPS $1.31, in line with expectations. TEL AVIV, Feb 5- Teva Pharmaceutical Industries is ready to return to making acquisitions, it said on Thursday, after a year of focusing on costs under its new chief executive. The company posted fourth-quarter earnings of $1.31 per diluted share, excluding one-time items, against $1.42 a year earlier.

  • Feb 5- Drugmaker Pfizer Inc said it would buy Hospira Inc for about $15 billion to boost its portfolio of generic injectible drugs and biosimilars, or copies of biotech drugs. Pfizer offered $90 per share in cash, a 39 percent premium to Hospira's closing stock price on Wednesday. Hospira soared 35 percent to near $88 before the bell Thursday, while Pfizer was up 3.6...

  • GSK sales falls; firm upbeat on respiratory unit Wednesday, 4 Feb 2015 | 8:45 AM ET

    Shares of GlaxoSmithKline jumped on Wednesday, despite the company posting a 3 percent fall in full-year revenue.

  • *Novartis deal on track to close in first half 2015. GSK is also banking on an asset swap with Novartis to help revive its fortunes, and looking to unlock value by floating its HIV unit ViiV Healthcare. GSK is buying vaccines, selling cancer drugs and forming a consumer health joint venture with Novartis in a $20- billion transaction designed to ensure more stable...

  • LONDON, Feb 4- GlaxoSmithKline said on Wednesday it expected to start to regain market share in respiratory medicine after weak demand for lung drug Advair again hurt fourth-quarter sales, capping a rough year for Britain's top drugmaker. GSK is also banking on an asset swap with Novartis to help revive its fortunes, and looking to unlock value by floating its...

  • CHICAGO, Feb 4- After successfully treating four Ebola patients last year, Emory University in Atlanta is now leading a government-funded project that will use blood from survivors of the deadly virus to test a novel way of treating infectious disease. The Defense Advanced Research Projects Agency, the Pentagon's elite research arm, has awarded Emory up to...

  • *Novartis: received pre-notification from health ministry. *Novartis says financial impact would be manageable. ZURICH, Feb 3- Swiss drugmaker Novartis said on Tuesday its Japanese business faced suspension by the country's health ministry but that it could manage the financial impact of such a sanction.

  • *AstraZeneca working with academic groups and Thermo Fisher. LONDON, Jan 29- AstraZeneca said on Thursday it had struck four research agreements in the hot area of genome editing as it bets on a new "genetic scissors" technology to deliver better and more precise drugs for a range of diseases. The collaborations with Britain's Wellcome Trust Sanger Institute, the...

  • *CEO says Roche committed to Switzerland despite franc rise. While cross-town rival Novartis has said it will review its Swiss cost base, Roche Chief Executive Severin Schwan said his company had no plans to move operations. "I continue to believe that Switzerland and Basel offer a very good framework for our business," Schwan told reporters.

  • Midday movers: Lockheed Martin, Plantronics & more Tuesday, 27 Jan 2015 | 1:05 PM ET
    Wall Street subway station NYSE

    Some of Tuesday's midday movers:

  • European stocks end lower after US earning misses Tuesday, 27 Jan 2015 | 11:41 AM ET

    European markets closed down on Tuesday, after a number of Wall Street's biggest firms missed earnings expectations.

  • Novartis flags faster sales, profit growth for 2015 Tuesday, 27 Jan 2015 | 2:48 AM ET
    Joe Jimenez, CEO of Novartis, at 2015 WEF in Davos, Switzerland.

    Novartis forecast sales and profits to grow at a faster pace this year driven by recent drug successes and its portfolio overhaul.

  • *Core EPS $1.21 vs $1.18 forecast in Reuters poll. ZURICH, Jan 27- Swiss drugmaker Novartis forecast sales and profits to grow at a faster pace this year as recent drug successes and its portfolio overhaul help it weather the impact of generic competition. Novartis unveiled a transformative series of deals last year which will see it focus on a smaller number of...

  • We're looking for bolt-on acquisitions: Novartis CEO

    Joe Jimenez, CEO of Novartis, says the company is looking to carry out merger and acquisition deals in 2015 to compliment its existing businesses.

  • Novartis CEO on euro, Swiss franc effect   Tuesday, 27 Jan 2015 | 1:45 AM ET
    Novartis CEO on euro, Swiss franc effect

    Joe Jimenez, CEO of Novartis, says currency moves won't affect the growth of the underlying business.

  • NEW YORK, Jan 26- A new wave of experimental cancer drugs that directly recruit the immune system's powerful T cells are proving to be immensely effective weapons against tumors, potentially transforming the $100 billion global market for drugs that fight the disease. But top oncology researchers are concerned about the two emerging technologies, citing...